Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Revive Therapeutics Ltd.
C.RVV
Alternate Symbol(s):
RVVTF
Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is...
advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:RVV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 19, 2022 1:03pm
TDR tweet re: AGM
https://twitter.com/TheDalesReport/status/1571891648392581123https://twitter.com/TheDalesReport/status/1571891648392581123
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 19, 2022 6:46am
AGM info ...
#Bucillamine https://countle.com/VdF3dmWLz
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(164)
•••
MyAli4s
X
View Profile
View Bullboard History
Comment by
MyAli4s
on Sep 19, 2022 6:21am
RE:Revive's Bucillamine EUA Very Soon !! GLTA Folks !!!
If Buccilamine had any effect on c19, it would be known already!
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 18, 2022 8:07pm
Revive's Bucillamine EUA Very Soon !! GLTA Folks !!!
#Bucillamine
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 17, 2022 8:28pm
That was LIFE then .... GLTA Monday - better news, hopefully
https://www.youtube.com/watch?v=9Y46Y1aXQQw&list=RD9Y46Y1aXQQw&start_radio=1&ab_channel=MysticPlugRecords
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 17, 2022 1:46pm
$RVV - Interesting Twitter post !
https://twitter.com/AaronBoniecki/status/1571151621270425600/photo/1
(17)
•••
Unimaginatively
X
View Profile
View Bullboard History
Post by
Unimaginatively
on Sep 16, 2022 3:01pm
RE:RE:RE: A BETTER SAFER PLAY : $SILO
TOTAL STEAL AT .03 CENTS.
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 16, 2022 7:19am
TDR - Phase 3 Trial For COVID Officially Enters ...
#Bucillamine https://thedalesreport.com/psychedelics/revive-therapeutics-phase-3-trial-for-covid-officially-enters-the-regulatory-funnel/
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 16, 2022 6:27am
$RVV Provides Update on the Psilocybin Clinical Study
https://ca.finance.yahoo.com/news/revive-therapeutics-provides-psilocybin-clinical-100000794.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 16, 2022 6:00am
New Press Release - Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 15, 2022 6:30pm
New Press Release - CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING
Toronto, Ontario--(Newsfile Corp. - Le 15 septembre 2022/September 2022) - The quarterly rebalancing of the CSE 25 Index will result in the following changes, effective after the close on Friday, September 16, 2022. Le rééquilibrage trimestriel de l’indice composé du CSE 25 entraînera les...
read article.
(36)
•••
WeedKing81
X
View Profile
View Bullboard History
Post by
WeedKing81
on Sep 15, 2022 2:50pm
THE DALES REPORT! $$$
https://thedalesreport.com/psychedelics/revive-therapeutics-phase-3-trial-for-covid-officially-enters-the-regulatory-funnel/
(42)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Comment by
ENEMENEMYNEMO
on Sep 14, 2022 7:56am
RE:Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
OMG If we have favourable statistical data to show an early resolution of PCR testing it would be a game changer for the world. Many lives would be saved...This is Great news today!!!
(42)
•••
cool888
X
View Profile
View Bullboard History
Post by
cool888
on Sep 14, 2022 6:38am
Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
#Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-announces-submission-amended-100000486.html
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 14, 2022 6:00am
New Press Release - Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has...
read article.
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results